Public Employees Retirement System of Ohio Has $13.10 Million Stake in Quest Diagnostics Incorporated $DGX

Public Employees Retirement System of Ohio raised its holdings in Quest Diagnostics Incorporated (NYSE:DGX) by 3.7% in the first quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 66,849 shares of the medical research company’s stock after purchasing an additional 2,407 shares during the period. Public Employees Retirement System of Ohio owned approximately 0.06% of Quest Diagnostics worth $13,101,000 at the end of the most recent quarter.

Several other hedge funds also recently made changes to their positions in the business. Norges Bank acquired a new stake in shares of Quest Diagnostics in the fourth quarter valued at approximately $229,522,000. Boston Partners grew its position in Quest Diagnostics by 32.8% during the third quarter. Boston Partners now owns 4,036,881 shares of the medical research company’s stock worth $767,978,000 after buying an additional 997,033 shares in the last quarter. EdgePoint Investment Group Inc. increased its stake in Quest Diagnostics by 95.5% during the 4th quarter. EdgePoint Investment Group Inc. now owns 1,661,072 shares of the medical research company’s stock worth $288,246,000 after acquiring an additional 811,320 shares during the period. UBS Group AG raised its holdings in Quest Diagnostics by 67.8% in the 4th quarter. UBS Group AG now owns 1,114,451 shares of the medical research company’s stock valued at $193,391,000 after acquiring an additional 450,161 shares in the last quarter. Finally, Bank of America Corp DE raised its holdings in Quest Diagnostics by 36.3% in the 2nd quarter. Bank of America Corp DE now owns 1,599,602 shares of the medical research company’s stock valued at $287,337,000 after acquiring an additional 426,399 shares in the last quarter. 88.06% of the stock is owned by institutional investors.

Insider Transactions at Quest Diagnostics

In other news, SVP Karthik Kuppusamy sold 8,147 shares of the firm’s stock in a transaction that occurred on Thursday, June 4th. The shares were sold at an average price of $200.00, for a total value of $1,629,400.00. Following the sale, the senior vice president directly owned 13,510 shares in the company, valued at approximately $2,702,000. This trade represents a 37.62% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO J. E. Davis sold 10,000 shares of Quest Diagnostics stock in a transaction that occurred on Monday, June 1st. The shares were sold at an average price of $194.14, for a total transaction of $1,941,400.00. Following the sale, the chief executive officer directly owned 132,423 shares in the company, valued at $25,708,601.22. This trade represents a 7.02% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 0.88% of the stock is currently owned by corporate insiders.

Key Stories Impacting Quest Diagnostics

Here are the key news stories impacting Quest Diagnostics this week:

• Positive Sentiment: Quest Diagnostics posted Q2 results that beat Wall Street expectations on both revenue and earnings, helped by stronger demand for routine diagnostic and preventive testing. The company also raised its full-year 2026 outlook, which investors are reading as evidence that growth is holding up well. Article: Quest Diagnostics Reports Second Quarter 2026 Financial Results; Raises Revenue and EPS Guidance for Full Year 2026
• Positive Sentiment: Mizuho raised its price target on DGX to $260 and kept an outperform rating, signaling confidence that the company can still outperform from here. Article: Quest Diagnostics price target raised by Mizuho
• Positive Sentiment: Truist also lifted its target to $250, while Robert W. Baird increased its target to $255, reflecting continued analyst optimism after the earnings beat and raised guidance. Article: Quest Diagnostics price target raised by Truist Financial Corporation
• Neutral Sentiment: Several market commentary pieces highlighted DGX as a momentum stock and noted the shares recently reached a 52-week high. That supports bullish sentiment, but these articles are mostly follow-up coverage rather than a new fundamental catalyst. Article: Are You Looking for a Top Momentum Pick? Why Quest Diagnostics (DGX) Is a Great Choice

Quest Diagnostics Trading Up 0.1%

Shares of DGX opened at $228.05 on Monday. The company has a debt-to-equity ratio of 0.72, a quick ratio of 1.46 and a current ratio of 1.59. Quest Diagnostics Incorporated has a 52-week low of $165.78 and a 52-week high of $237.78. The firm has a market cap of $25.17 billion, a price-to-earnings ratio of 24.21, a PEG ratio of 2.61 and a beta of 0.58. The business’s fifty day moving average is $203.23 and its 200-day moving average is $197.76.

Quest Diagnostics (NYSE:DGX) last announced its quarterly earnings data on Thursday, July 23rd. The medical research company reported $3.12 earnings per share for the quarter, topping the consensus estimate of $2.82 by $0.30. The business had revenue of $3.04 billion during the quarter, compared to the consensus estimate of $2.97 billion. Quest Diagnostics had a return on equity of 16.01% and a net margin of 9.18%.Quest Diagnostics’s revenue for the quarter was up 10.2% on a year-over-year basis. During the same period in the prior year, the company earned $2.62 EPS. Quest Diagnostics has set its FY 2026 guidance at 11.050-11.250 EPS. Equities analysts anticipate that Quest Diagnostics Incorporated will post 11.17 EPS for the current fiscal year.

Quest Diagnostics Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Wednesday, July 22nd. Stockholders of record on Wednesday, July 8th were issued a $0.86 dividend. The ex-dividend date of this dividend was Wednesday, July 8th. This represents a $3.44 dividend on an annualized basis and a dividend yield of 1.5%. Quest Diagnostics’s dividend payout ratio is 36.52%.

Analyst Ratings Changes

Several research firms have recently issued reports on DGX. Jefferies Financial Group reissued a “buy” rating and set a $245.00 target price on shares of Quest Diagnostics in a report on Thursday. Wall Street Zen downgraded Quest Diagnostics from a “buy” rating to a “hold” rating in a research note on Monday, July 20th. Mizuho upped their price objective on shares of Quest Diagnostics from $235.00 to $260.00 and gave the stock an “outperform” rating in a research report on Friday. Weiss Ratings upgraded shares of Quest Diagnostics from a “buy (b)” rating to a “buy (b+)” rating in a research note on Thursday, July 9th. Finally, UBS Group reissued a “neutral” rating and issued a $232.00 target price on shares of Quest Diagnostics in a report on Friday. Six research analysts have rated the stock with a Buy rating and six have given a Hold rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $231.73.

Quest Diagnostics Profile

Quest Diagnostics (NYSE: DGX) is a leading provider of diagnostic information services that supports clinical decision-making for patients, physicians and healthcare organizations. The company operates a network of clinical laboratories and patient service centers that perform a broad range of laboratory tests and diagnostic assays used in routine care, disease diagnosis, monitoring and screening.

Its services span core clinical laboratory testing, anatomic pathology, molecular and genomic diagnostics, infectious disease testing and toxicology.